This is the first large real-world study of >300 000 patients with type 2 diabetes mellitus, both with and without established cardiovascular disease, from routine clinical practice across 6 countries, evaluating the outcomes of hospitalization for heart failure (HHF) and all-cause death in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) versus other glucose-lowering drugs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.